Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	1/16/2009 6:10:22 PM
	Read Replies (1) of 10280

Merrill, 1/14 Rating Changes Sepracor Inc. (SEPR, US$13.37, C-2-9) Upgrading SEPR to Neutral. We are upgrading Sepracor Inc. from Underperform to Neutral & Raising PO from $13 to $15. In our view, investors are already well aware of disappointing prescription trends for some of SEPR’s marketed products, which could lead to negative estimate revisions for revenues. With the stock down almost 60% in ‘08, it is tough to imagine investor sentiment getting much worse than it has been recently. We believe that sentiment & stock performance could improve in ’09 based on some combination of cost control initiatives, as SG&A & R&D as a percentage of sales are high relative to the sector, progression of the R&D pipeline, & business development

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next